Daily Newsletter

21 November 2023

Daily Newsletter

21 November 2023

Ingestible pill that monitors vitals yields positive results in human trial

Data wirelessly collected from the pill inside the stomach demonstrated it can accurately detect respiration and cardiac rate.

Robert Barrie November 20 2023

An ingestible pill that monitors vital signs from inside the body has produced positive results from a first-in-human study.

The data, published on 17 November in the journal Device, demonstrates that the mini sensor could replace intrusive, wearable sensors in sleep studies.

Developed by Celero Systems, the VM pill was investigated by researchers at the Department of Mechanical Engineering at Massachusetts Institute of Technology in the US in patients scheduled for a sleep study. It works by detecting vibrations in the body and wirelessly transmitting data signals to a computer.

The device, the size of a vitamin capsule, was tested in the stomachs of ten patients at the West Virginia University Sleep Evaluation Centre. A total of 57 hours of pill data was logged across the subject group.

The researchers reported that when compared to standard wearable monitoring devices, the device was able to monitor respiration rate and heart rate with an accuracy of 92.7% and 96.2% respectively.

Diagnosing sleep disorders usually requires patients to stay overnight in a sleep lab hooked up to sensors and machines. Researchers suggest that the pill could provide a less intrusive way to collect accurate sleep data.

Radiographic imaging performed two weeks after the capsules were swallowed showed that all ten patients had naturally excreted the pill.

The researchers highlighted further results from an animal study, also part of the paper, that indicate a potential use in the detection of opioid-induced respiratory depression.  

Speaking to MIT News, associate professor of mechanical engineering at MIT and senior author of the study Giovanni Traverso said: “It’s an exciting intervention to help people be diagnosed and then receive the appropriate treatment if they suffer from obstructive sleep apnoea.”

“The device also has the potential for early detection of changes in respiratory status, whether it’s a result of opiates or other conditions that could be monitored, like asthma or chronic obstructive pulmonary disease.”

Can Generative AI transform the medical devices industry?

The healthcare, pharma, and medical devices industries are often risk-averse compared to other sectors when adopting new technologies. However, mainly due to COVID-19, these sectors have witnessed an acceleration in digital transformation, which has improved efficiencies and enhanced patient outcomes. AI can revolutionize the drug discovery process and significantly reduce the time and cost to get a drug to market, particularly in areas of unmet need. There is also huge potential for AI in medical diagnostics. However, using healthcare data for AI development raises data privacy concerns.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close